‘Stay in the shade': El Dorado County Fire Protection advises against hiking on remote trails
(FOX40.COM) — The National Weather Service has issued a Heat Advisory for the Sacramento Valley into El Dorado County starting Friday late morning and lasting until Saturday night.
The El Dorado County Fire Protection District stated that they are advising people not to try their new hiking shoes on a remote trail.
Defense Intelligence Agency IT Specialist arrested for allegedly sharing classified information
EDCFPD said, 'Stay in the shade or inside of you are sensitive to the heat. Drink plenty of water or hydrating fluids.'
According to FOX40 Chief Meteorologist Adam Epstein, the temperature will be in the high 99s to 107 with warm lows in the 60s and 70s. On Sunday, we can expect to see a cool down with temperatures being at the 80s.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fox News
10 minutes ago
- Fox News
Behar says Dem effort to reclaim men is a 'waste of money,' suggests 'teaching them to not be such sexists'
Co-hosts of ABC's "The View" on Friday feuded over how the Democratic Party should change its game plan after losing male voters. After their decisive defeat in November, Democrats are still figuring out how they should change their strategy and move forward as a party. The New York Times recently published a report claiming that Democrats are spending $20 million on a study called "Speaking with American Men: A Strategic Plan." The study is a project to "study the syntax, language and content that gains attention and virality in these spaces" of male voters. Co-host Joy Behar scoffed at the idea, deriding it as "20 million bucks just to talk to boys." "You know what I think? I think it's a waste of money. Maybe these guys should spend their money on teaching men to not be such sexists," Behar said, as the audience applauded. "But the stats don't bear that out," co-host Alyssa Farah Griffin said, arguing that Trump has done better with multiple demographics across races and sexes than his Republican predecessors did. Behar suggested this was merely because he was "running against a woman." "You think Democrats that were with Biden in 2020 left to be with Trump because they're sexist?" Griffin asked. "I don't know the reason, but it's very suspicious," Behar replied. Other co-hosts argued that Democrats have indeed alienated male voters. Griffin mocked the idea of appealing to authenticity by hiring analysts and strategists to analyze how men speak, suggesting instead, "What made Joe Rogan or Theo Von or some of these manosphere guys huge was there's a level of authenticity." Meanwhile, she noted Democrats not only have an "authenticity problem" but recalled that "Joe Rogan was a Bernie Bro. Democrats lost him. They had their own Joe Rogan and then alienated him with policies." She added that men want to be able to speak about the issues they face as a group, particularly the phenomenon of men falling behind, without being accused of sexism or excluding women. Haines brought up the appeal of both Trump and the manosphere. "What drove people to this manosphere was people were saying, 'It's okay to be a man, you have value.' I think the language around men with 'toxic masculinity' were sometimes misunderstood to make men the problem."
Fox News
10 minutes ago
- Fox News
Former LSU gymnast Olivia Dunne in tears over stalking fears: 'I don't know what to do'
Former LSU gymnast Olivia "Livvy" Dunne says she's fearful she's being "stalked" by apparent superfans that seem to know the social media influencer's every move. Dunne, who boasts over 13 million followers across several social media platforms, posted a video on TikTok Friday explaining uncomfortable encounters she continues to have with "middle-aged men" at airports. "I fear that I'm being stalked, and I don't know what to do. It's gotten to the point that every single time I go to the airport there's a group of at least 10 middle-aged men waiting for me, and they harass me," she explained in the video with over a million views. "It's these men that want my autograph," she continued. "They have a stack of like 40 pictures of me or my magazines, and they will run after me down the TSA pre-check line and yell at me if I don't give them my autograph. It's insane." Dunne included a video from her most recent trip to the airport that left her in tears after she claimed they "circled me at the baggage claim and were like in my face." "It's something with the airline, and it's weird," she speculated before adding, "It needs to stop, because it's scary for girls. It's weird." Just last month, Dunne announced the end of her gymnastics career after LSU failed to successfully defend the NCAA championship title. The fifth-year senior did not compete in the competition after she was sidelined in March by an "avulsion fracture" in her patella. Dunne, who is dating Pittsburgh Pirates pitching sensation Paul Skenes, was one of the NCAA's top NIL earners and boasted millions of followers across several social media platforms. She played a role in helping LSU win its first NCAA title last year. Follow Fox News Digital's sports coverage on X, and subscribe to the Fox News Sports Huddle newsletter.
Yahoo
11 minutes ago
- Yahoo
Daiichi Sankyo Continues to Transform Treatment Landscape for Patients with Cancer with Practice-Changing Data at ASCO
Late-breaking data from DESTINY-Breast09 and DESTINY-Gastric04 phase 3 trials showcase how ENHERTU will potentially redefine standard of care for first-line HER2 positive metastatic breast cancer and second-line HER2 positive metastatic gastric cancer Investor meeting to discuss ASCO presentations and oncology development updates BASKING RIDGE, N.J., May 22, 2025--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) will present new clinical research across its oncology portfolio with more than 20 abstracts in multiple cancers at the 2025 American Society of Clinical Oncology Scientific Program (#ASCO25). Data at ASCO showcasing the company's progress towards creating new standards of care for patients with cancer will include two late-breaking oral presentations. The first will feature results of the DESTINY-Breast09 phase 3 trial (LBA #1008) where ENHERTU® (trastuzumab deruxtecan) in combination with pertuzumab demonstrated superior progression-free survival compared to taxane, trastuzumab and pertuzumab (THP) as a first-line treatment in patients with HER2 positive metastatic breast cancer. The second will highlight results of the DESTINY-Gastric04 phase 3 trial (LBA #4002) where ENHERTU demonstrated superior overall survival compared to ramucirumab and paclitaxel as a second-line treatment in patients with HER2 positive metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. Data from DESTINY-Breast09 and DESTINY-Gastric04 will be featured in ASCO press briefings. "This year's ASCO marks the fourth in a row where potential practice-changing ENHERTU data will be showcased," said Ken Takeshita, MD, Global Head, R&D, Daiichi Sankyo. "With the results of DESTINY-Breast09 and DESTINY-Gastric04, we now have six breast and two gastric cancer randomized trials that have demonstrated significant survival improvements with ENHERTU. These data, along with other updates across our industry-leading oncology portfolio, underscore our commitment to pushing the boundaries of science to create new medicines or combination strategies that improve outcomes for patients with cancer." Other ENHERTU data at ASCO will include an oral presentation featuring an exploratory circulating tumor DNA analysis of the DESTINY-Breast06 phase 3 trial (#1013) evaluating ENHERTU compared to physician's choice of chemotherapy in hormone receptor (HR) positive, HER2 low (IHC 1+ or IHC 2+/ISH-) or HER2 ultralow (IHC 0 with membrane staining) metastatic breast cancer. Updated results from the PRO-DUCE study (#1545) examining vital sign monitoring compared to usual care in patients with metastatic breast cancer receiving ENHERTU also will be highlighted as a poster presentation. A trials-in-progress poster presentation will feature the DESTINY-Gastric05 phase 3 trial (TPS4207) evaluating ENHERTU in combination with a fluoropyrimidine-based chemotherapy and pembrolizumab compared to trastuzumab in combination with platinum-based chemotherapy and pembrolizumab in previously untreated patients with unresectable, locally advanced or metastatic HER2 positive (IHC 3+ or IHC 2+/ISH+) gastric or GEJ cancer. Progress in Lung Cancer Across Daiichi Sankyo's DXd ADC PortfolioUpdated DATROWAY® (datopotamab deruxtecan) combination data across three early-phase trials will be highlighted in patients with early or advanced non-small cell lung cancer (NSCLC). Updated results from the TROPION-Lung02 phase 1b trial (#8501) evaluating DATROWAY plus pembrolizumab with or without platinum-based chemotherapy in patients with previously untreated advanced NSCLC without actionable genomic alterations will be featured as an oral presentation. This will include results from an exploratory analysis using quantitative continuous scoring (QCS), AstraZeneca's proprietary computational pathology platform. Poster sessions will highlight the first presentation of data of DATROWAY and rilvegostomig, AstraZeneca's PD-1/TIGIT bispecific antibody, from the TROPION-Lung04 phase 1b trial (#8521) cohort evaluating the combination in patients without actionable genomic alterations who have advanced or metastatic NSCLC, and the final pathologic complete response and major pathologic response data from the NeoCOAST-2 phase 2 trial (#8046) evaluating DATROWAY with durvalumab, AstraZeneca's anti-PD-L1 therapy, and chemotherapy as neoadjuvant treatment followed by adjuvant treatment with durvalumab in patients with resectable early-stage (IIA to IIIB) NSCLC. Additional lung cancer data at ASCO will include an oral presentation of the HERTHENA-Lung02 phase 3 trial (#8506) of patritumab deruxtecan (HER3-DXd) versus platinum doublet chemotherapy in patients with locally advanced or metastatic EGFR-mutated NSCLC with disease progression following the use of an EGFR tyrosine kinase inhibitor (TKI). Trials-in-progress poster presentations in lung cancer across the DXd ADC portfolio will include the TROPION-Lung14 phase 3 trial (TPS8647) evaluating DATROWAY combined with osimertinib, AstraZeneca's EGFR TKI, compared to osimertinib alone in the first-line setting of patients with locally advanced or metastatic EGFR-mutated NSCLC and a substudy of KEYMAKER-U01, a phase 1/2 trial (TPS8652), evaluating pembrolizumab plus ifinatamab deruxtecan (I-DXd) or patritumab deruxtecan with or without chemotherapy in patients with untreated advanced NSCLC. Additional Data and Trials-in-Progress Across Daiichi Sankyo's Oncology Portfolio at ASCOOral presentations also will highlight initial results from the TUXEDO-3 phase 2 trial (#2005) evaluating patritumab deruxtecan in patients with metastatic breast cancer or advanced NSCLC and active brain metastases and in patients with leptomeningeal carcinomatosis/disease from advanced solid tumors, as well as results from a phase 1 trial (#10003) evaluating valemetostat, a dual EZH1 and EZH2 inhibitor, in pediatric patients with malignant solid tumors. Additional DXd ADC trials-in-progress poster presentations include the REJOICE-PanTumor01 phase 2 trial (TPS3158) evaluating raludotatug deruxtecan (R-DXd) in patients with locally advanced or metastatic gynecologic or genitourinary cancers, IDeate-PanTumor02 phase 1b/2 trial (TPS3157) evaluating ifinatamab deruxtecan in patients with recurrent or metastatic solid tumors and a substudy of KEYMAKER-U06, a phase 1/2 trial (TPS4209) evaluating ifinatamab deruxtecan in combination with pembrolizumab with or without chemotherapy in patients with advanced esophageal squamous cell carcinoma. Other trials-in-progress posters include the QuANTUM-Wild phase 3 trial (TPS6580) evaluating VANFLYTA® (quizartinib) in combination with chemotherapy in patients with FLT3-ITD negative acute myeloid leukemia and a first-in-human phase 1 trial of DS-2243 (TPS2668), a potential first-in-class bispecific T-cell engager targeting HLA-A*02/NY-ESO in patients with advanced solid tumors. Daiichi Sankyo will hold a virtual conference call for investors on Monday, June 2, 2025 from 6:00 to 7:15 pm CDT / Tuesday, June 3, 2025 from 8:00 to 9:15 am JST. Executives from Daiichi Sankyo will provide an overview of the ASCO research data and address questions. Details of the two late-breaking ENHERTU oral presentations at ASCO 2025 include: Presentation Title Author Abstract Presentation (CDT) LBAs Trastuzumab deruxtecan (T-DXd) + pertuzumab vs taxane + trastuzumab + pertuzumab (THP) for first-line treatment of patients with human epidermal growth factor receptor 2 positive (HER2+) advanced/metastatic breast cancer: interim results from DESTINY-Breast09 S. Tolaney LBA1008 Special LBA Session Oral Presentation Monday, June 2 7:30 – 8:00 am Trastuzumab deruxtecan (T-DXd) vs ramucirumab plus paclitaxel in second-line treatment of patients with human epidermal growth factor receptor 2 positive (HER2+) unresectable/metastatic gastric cancer or gastroesophageal junction adenocarcinoma: primary analysis of the randomized, phase 3 DESTINY-Gastric04 study K. Shitara LBA4002 Oral Presentation Saturday, May 31 3:00 – 6:00 pm Highlights of additional clinical data and trials-in-progress from Daiichi Sankyo's oncology pipeline include: Presentation Title Author Abstract Presentation (CDT) Breast Exploratory biomarker analysis of trastuzumab deruxtecan (T-DXd) vs physician's choice of chemotherapy in HER2 low/ultralow, hormone receptor-positive (HR+) metastatic breast cancer in DESTINY-Breast06 R. Dent 1013 Oral Presentation Saturday, May 31 1:15 – 4:15 pm HERTHENA-Breast03: a phase 2, randomized, open-label study evaluating neoadjuvant patritumab deruxtecan + pembrolizumab before or after pembrolizumab + chemotherapy for early-stage TNBC or HR-low+/HER2- breast cancer J. O'Shaughnessy TPS629 Poster Session Monday, June 2 9:00 am – 12:00 pm Electronic patient-reported outcomes with vital sign monitoring versus usual care during trastuzumab deruxtecan treatment for metastatic breast cancer: updated results from the PRO-DUCE study Y. Kikawa 1545 Poster Session Sunday, June 1 9:00 am – 12:00 pm Lung TROPION-Lung02: datopotamab deruxtecan (Dato-DXd) plus pembrolizumab with or without platinum chemotherapy as first-line therapy for advanced non-small cell lung cancer B. Levy 8501 Oral Presentation Sunday, June 1 8:00 – 11:00 am Patritumab deruxtecan (HER3-DXd) in resistant EGFR-mutated advanced non-small cell lung cancer after a third-generation EGFR TKI: the phase 3 HERTHENA-Lung02 study T. Mok 8506 Oral Presentation Sunday, June 1 8:00 – 11:00 am First-line datopotamab deruxtecan (Dato-DXd) + rilvegostomig in advanced or metastatic non-small cell lung cancer: results from TROPION-Lung04 (cohort 5) S. Waqar 8521 Poster Session Saturday, May 31 1:30 – 4:30 pm TROPION-Lung14: a phase 3 study of osimertinib ± datopotamab deruxtecan (Dato-DXd) as first-line treatment for patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer S. Lu TPS8647 Poster Session Saturday, May 31 1:30 – 4:30 pm Neoadjuvant durvalumab + chemotherapy + novel anticancer agents and adjuvant durvalumab ± novel agents in resectable non-small cell lung cancer: updated outcomes from NeoCOAST-2 T. Cascone 8046 Poster Session Saturday, May 31 1:30 – 4:30 pm KEYMAKER-U01 substudy 01A: phase 1/2 study of pembrolizumab plus ifinatamab deruxtecan (I-DXd) or patritumab deruxtecan (HER3-DXd) with or without chemotherapy in untreated stage IV non-small cell lung cancer C. Aggarwal TPS8652 Poster Session Saturday, May 31 1:30 – 4:30 pm Gastric An open-label, randomized, multicenter, phase 3 study of trastuzumab deruxtecan (T-DXd) + chemotherapy ± pembrolizumab versus chemo + trastuzumab ± pembro in first-line metastatic HER2+ gastric or gastroesophageal junction cancer: DESTINY-Gastric05 K. Shitara TPS4207 Poster Session Saturday, May 31 9:00 am – 12:00 pm Esophageal KEYMAKER-U06 substudy 06E: phase 1/2 open-label, umbrella platform study of ifinatamab deruxtecan in combination with pembrolizumab with or without chemotherapy for first-line treatment of advanced esophageal squamous cell carcinoma K. Kato TPS4209 Poster Session Saturday, May 31 9:00 am – 12:00 pm AML QuANTUM-Wild: a phase 3, randomized, double-blind, placebo-controlled trial of quizartinib in combination with chemotherapy and as single-agent maintenance in FLT3-ITD negative acute myeloid leukemia P. Montesinos TPS6580 Poster Session Sunday, June 1 9:00 am – 12:00 pm Pan-Tumor Patritumab deruxtecan (HER3-DXd) in active brain metastases from metastatic breast and non-small cell lung cancers, and leptomeningeal disease from advanced solid tumors: results from the TUXEDO-3 phase 2 trial M. Preusser 2005 Oral Presentation Friday, May 30 2:45 – 5:45 pm IDeate-PanTumor02: a phase 1b/2 study to evaluate the efficacy and safety of ifinatamab deruxtecan (I-DXd) in patients with recurrent or metastatic solid tumors T. Kogawa TPS3157 Poster Session Monday, June 2 1:30 – 4:30 pm REJOICE- PanTumor01: a phase 2 signal-seeking study of raludotatug deruxtecan (R-DXd) in patients with advanced or metastatic gynecologic or genitourinary tumors L. Albiges TPS3158 Poster Session Monday, June 2 1:30 – 4:30 pm A phase 1, first-in-human study of DS-2243, an HLA-A*02/NY-ESO directed bispecific T‑cell engager, in patients with advanced solid tumors S. D'Angelo TPS2668 Poster Session Monday, June 2 1:30 – 4:30 pm Pediatric Safety and efficacy of the EZH1/2 inhibitor valemetostat tosylate (DS-3201b) in pediatric patients with malignant solid tumors (NCCH1904): a multicenter phase 1 trial A. Arakawa 10003 Oral Presentation Saturday, May 31 3:00 – 6:00 pm About the ADC Portfolio of Daiichi SankyoThe Daiichi Sankyo ADC portfolio consists of seven ADCs in clinical development crafted from two distinct ADC technology platforms discovered in-house by Daiichi Sankyo. The ADC platform furthest in clinical development is Daiichi Sankyo's DXd ADC Technology where each ADC consists of a monoclonal antibody attached to a number of topoisomerase I inhibitor payloads (an exatecan derivative, DXd) via tetrapeptide-based cleavable linkers. The DXd ADC portfolio currently consists of ENHERTU, a HER2 directed ADC, and DATROWAY, a TROP2 directed ADC, which are being jointly developed and commercialized globally with AstraZeneca. Patritumab deruxtecan (HER3-DXd), a HER3 directed ADC, ifinatamab deruxtecan (I-DXd), a B7-H3 directed ADC, and raludotatug deruxtecan (R-DXd), a CDH6 directed ADC, are being jointly developed and commercialized globally with Merck & Co., Inc, Rahway, NJ, USA. DS-3939, a TA-MUC1 directed ADC, is being developed by Daiichi Sankyo. The second Daiichi Sankyo ADC platform consists of a monoclonal antibody attached to a modified pyrrolobenzodiazepine (PBD) payload. DS-9606, a CLDN6 directed PBD ADC, is the first of several planned ADCs in clinical development utilizing this platform. Ifinatamab deruxtecan, patritumab deruxtecan, raludotatug deruxtecan, DS-3939 and DS-9606 are investigational medicines that have not been approved for any indication in any country. Safety and efficacy have not been established. About Daiichi SankyoDaiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops and delivers new standards of care to enrich the quality of life around the world. With more than 125 years of experience, Daiichi Sankyo leverages its world-class science and technology to create new modalities and innovative medicines for people with cancer, cardiovascular and other diseases with high unmet medical needs. For more information, please visit View source version on Contacts Media Contacts: Global/US Media: Jennifer BrennanDaiichi Sankyo, + 1 908 900 3183 (mobile) Japan: Daiichi Sankyo Co., Investor Relations Contact: DaiichiSankyoIR_jp@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
